US-based immunotherapy developer Immunai received $60m in a series A round on Thursday co-led by speciality pharmaceutical firm Dexcel Pharma.
Schusterman Family Investments, Duquesne Family Office and Catalio Capital Management co-led the round, which also attracted Viola Ventures and TLV Partners.
Founded in 2018, Immunai’s technology combines high-resolution single-cell analytics with machine learning to uncover insights into the regulation and function of the immune system to make immunotherapies more effective. It collects the data in a proprietary database called Amica.
The series A capital will serve to expand Amica and Immunai will also look to bolster its functional genomics capabilities. Kenan Turnacioglu, general partner at Catalio, has joined the board of directors.
Noam Solomon, co-founder and CEO of Immunai, said: “The immune system is implicated in nearly every illness, making our technology critical for identifying, diagnosing and treating disease, from cancer and infectious disease to autoimmune disorders.”
Immunai previously obtained $20m in seed funding co-led by Viola Ventures and TLV Partners in May 2020.
